MAPT and Alzheimer disease: Regarding plasma tau biomarkers, it was reported that the levels of plasma phospho-tau 217 and phospho-tau 181 were correlated with tau PET and CSF Aβ1–42/Aβ1–40 ratio in LBD [82], suggesting plasma phospho-tau may be useful to detect AD co-pathology in patients with LBD.